Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions: HemaMax, Placebo; Biological · Drug
Lead sponsor: Neumedicines Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
Interventions: ALXN1101, Placebo; Drug
Lead sponsor: Origin Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Subjects
Interventions: TD-1439, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Ulcerative Colitis
Interventions: Amg 181; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more

Conditions: Healthy
Interventions: PF-06427878, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: Placebo, Favipiravir; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteer
Interventions: AVB-S6-500, Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Adults, Elderly Subjects
Interventions: TD-1439, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: Rivipansel; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pharmacokinetics
Interventions: TV-45070, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: QT Interval
Interventions: Telotristat etiprate, Placebo, Moxifloxacin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD4076, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: N91115, Placebo, Placebo-Day 1 only; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Cognitive Deficit
Interventions: Brain Stimulation; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Tramadol HCl, 50 mg, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: ATF936, AXT914; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Alzheimer's Disease
Interventions: Velusetrag, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy
Interventions: Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy
Interventions: TRV130, Moxifloxacin, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: TAK-994, TAK-994 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: HIV Infections
Interventions: apricitabine; Drug
Lead sponsor: Avexa; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Search by objective public record fields.

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

A Phase 1 AVB-S6-500 Safety and Tolerability Study

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

A Thorough QT Study of Telotristat Etiprate

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

Studying the Effects of Brain Stimulation on Cognitive Control and Associated EEG in Human Subjects.

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers

Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects